CHICAGO, Dec. 5 /PRNewswire/ -- Each year, major corporations and their insurance companies pay out hundreds of millions of dollars in litigation settlements and jury awards for mass-tort cases by workers claiming to have been harmed by exposure to chemicals. Now a new DNA technology promises to weed out frivolous claims from the legitimate ones, saving companies and their insurers millions on such payouts and prompting reasonable settlements and resolutions.
Dr. Bruce Gillis, CEO of the genomics research group, The Cytokine Institute (TCI), is presenting a tutorial on the application of DNA lab-based evidence in workers' compensation and civil litigation at the American Bar Association's "National Program on National Trends" TIPS Staff Counsel CLE for 2008.
For the first time, litigators will tour TCI's affiliate laboratories at the University of Illinois College of Medicine at Chicago (UIC), on March 26 and 28, 2008, where they will gain hands-on experience of the new genomics- based technology, msds1(TM). The technology is already being used in some civil courts to weed out baseless lawsuits by identifying on a cellular level if an individual has suffered injury due to a specific chemical or toxic exposure.
By analyzing how 36,000 parameters of an individual's DNA are affected by specific chemicals -- including benzene, chromium, asbestos and formaldehyde -- this technology can determine with 99.9% certainty if a person was injuriously exposed to a particular toxin, thereby offering an objective methodology for providing scientifically-based evidence. Companies facing class-action and mass-tort lawsuits immediately benefit by knowing how chemicals and toxins in their workplace affect human health and the environment.
Sponsored by the ABA, and co-sponsored by the Workers' Injury Law &
Advocacy Group, The College of Workers' Compensation Lawyers, The National
Conference of the Administrative Law Judiciary, The American College of
'/>"/>
| SOURCE The Cytokine Institute Copyright©2007 PR Newswire. All rights reserved |